Accelerated biological ageing as a complication of cancer therapy
DOI:
https://doi.org/10.14739/2310-1210.2024.3.302542Keywords:
cancer, biological aging, replicative aging, antitumor therapy, markers of cellular senescence, coronary artery calciumAbstract
Aim. The paper aimed to update the study on accelerated biological aging as a complication of cancer therapy with a focus on diagnosing and prognosing the disease course.
The authors independently searched scientific literature for the systematic review within databases PubMed, Scopus and Cochrane in the period from 2018 to 2024, using combinations of keywords “cancer”, “biological aging”, “replicative aging”, “antitumor therapy”, “markers of cellular senescence”, “coronary artery calcium” and selected full-text publications written in English and Ukrainian with level 1–3 evidence.
People affected by cancer grow old faster. This could be related to malignant growth biology as well as to methods of anticancer therapy received. Cytostatics, targeted, hormonal and immune drugs damage not only malignant, but also benign cells, which leads to violations of replication with sustained cell cycle arrest and other phenotypic signs – macromolecular damage, metabolic changes, production of a specific senescence-associated secretome. Clinically, this is manifested by reduced work capacity, weakness, chronic organ dysfunction, cardiovascular disorders, progression of coronary atherosclerosis, hypertension, diabetes, dyslipidemia, sarcopenia, cognitive disorders, a de novo development of tumors and premature death. Biological markers of cellular senescence include the expression of lipofuscin, Ki67, p21 WAF1/Cip1 or p16 INK4a. A clinical marker of aging is the deposition of calcium salts within coronary arteries based on the Agatston score detected using multidetector computed tomography.
Conclusions. A better understanding of the cancer consequences associated with accelerated biological aging might suggest new therapeutic strategies and improve the quality of life among cancer survivors. Rehabilitation measures through changes in diet, caloric restriction, aerobic exercises and pharmacological senolytic therapy should be a part of a patient’s daily routine after completion of radical cancer treatment.
References
Stoczynska-Fidelus E, Węgierska M, Kierasińska A, Ciunowicz D, Rieske P. Role of Senescence in Tumorigenesis and Anticancer Therapy. J Oncol. 2022;2022:5969536. doi: https://doi.org/10.1155/2022/5969536
Schosserer M, Grillari J, Breitenbach M. The Dual Role of Cellular Senescence in Developing Tumors and Their Response to Cancer Therapy. Front Oncol. 2017;7:278. doi: https://doi.org/10.3389/fonc.2017.00278
Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585-621. doi: https://doi.org/10.1016/0014-4827(61)90192-6
Guo J, Huang X, Dou L, Yan M, Shen T, Tang W, et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduct Target Ther. 2022;7(1):391. doi: https://doi.org/10.1038/s41392-022-01251-0
Bhatia R, Holtan S, Jurdi NE, Prizment A, Blaes A. Do Cancer and Cancer Treatments Accelerate Aging? Curr Oncol Rep. 2022;24(11):1401-12. doi: https://doi.org/10.1007/s11912-022-01311-2
Von Ah D, Crouch A, Arthur E, Yang Y, Nolan T. Association Between Cardiovascular Disease and Cognitive Dysfunction in Breast Cancer Survivors. Cancer Nurs. 2023;46(2):E122-E128. doi: https://doi.org/10.1097/NCC.0000000000001083
Muhandiramge J, Zalcberg JR, van Londen GJ, Warner ET, Carr PR, Haydon A, et al. Cardiovascular Disease in Adult Cancer Survivors: a Review of Current Evidence, Strategies for Prevention and Management, and Future Directions for Cardio-oncology. Curr Oncol Rep. 2022;24(11):1579-92. doi: https://doi.org/10.1007/s11912-022-01309-w
Wang S, Prizment A, Thyagarajan B, Blaes A. Cancer Treatment-Induced Accelerated Aging in Cancer Survivors: Biology and Assessment. Cancers (Basel). 2021;13(3):427. doi: https://doi.org/10.3390/cancers13030427
Berben L, Floris G, Wildiers H, Hatse S. Cancer and Aging: Two Tightly Interconnected Biological Processes. Cancers (Basel). 2021;13(6):1400. doi: https://doi.org/10.3390/cancers13061400
Wang B, Kohli J, Demaria M. Senescent Cells in Cancer Therapy: Friends or Foes? Trends Cancer. 2020;6(10):838-57. doi: https://doi.org/10.1016/j.trecan.2020.05.004
Hill A, Sadda J, LaBarge MA, Hurria A. How cancer therapeutics cause accelerated aging: Insights from the hallmarks of aging. J Geriatr Oncol. 2020;11(2):191-3. doi: https://doi.org/10.1016/j.jgo.2019.03.007
Pedrosa MB, Barbosa S, Vitorino R, Ferreira R, Moreira-Gonçalves D, Santos LL. Chemotherapy-Induced Molecular Changes in Skeletal Muscle. Biomedicines. 2023;11(3):905. doi: https://doi.org/10.3390/biomedicines11030905
Lam T, Birzniece V, McLean M, Gurney H, Hayden A, Cheema BS. The Adverse Effects of Androgen Deprivation Therapy in Prostate Cancer and the Benefits and Potential Anti-oncogenic Mechanisms of Progressive Resistance Training. Sports medicine - open. 2020;6(1):13. doi: https://doi.org/10.1186/s40798-020-0242-8
Ruhland MK, Alspach E. Senescence and immunoregulation in the tumor microenvironment. Front Cell Dev Biol. 2021;9:754069. doi: https://doi.org/10.3389/fcell.2021.754069
Mannick JB, Lamming DW. Targeting the biology of aging with mTOR inhibitors. Nat Aging. 2023;3(6):642-60. doi: https://doi.org/10.1038/s43587-023-00416-y
Maddern AS, Coller JK, Bowen JM, Gibson RJ. The Association between the Gut Microbiome and Development and Progression of Cancer Treatment Adverse Effects. Cancers (Basel). 2023;15(17):4301. doi: https://doi.org/10.3390/cancers15174301
Yarosh R, Roesler MA, Murray T, Cioc A, Hirsch B, Nguyen P, et al. Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS). Cancer Causes Control. 2021;32(3):241-50. doi: https://doi.org/10.1007/s10552-020-01378-x
Lim H, Im M, Seo ES, Cho HW, Ju HY, Yoo KH, et al. Tandem High-Dose Chemotherapy Increases the Risk of Secondary Malignant Neoplasm in Pediatric Solid Tumors. Cancer Res Treat. 2024;56(2):642-51. doi: https://doi.org/10.4143/crt.2023.999
Murray J, Bennett H, Bezak E, Perry R. The role of exercise in the prevention of cancer therapy-related cardiac dysfunction in breast cancer patients undergoing chemotherapy: systematic review. Eur J Prev Cardiol. 2022;29(3):463-72. doi: https://doi.org/10.1093/eurjpc/zwab006
Chang L, Weiner LS, Hartman SJ, Horvath S, Jeste D, Mischel PS, Kado DM. Breast cancer treatment and its effects on aging. J Geriatr Oncol. 2019;10(2):346-55. doi: https://doi.org/10.1016/j.jgo.2018.07.010
Ali JH, Walter M. Combining old and new concepts in targeting telomerase for cancer therapy: transient, immediate, complete and combinatory attack (TICCA). Cancer Cell Int. 2023;23(1):197. doi: https://doi.org/10.1186/s12935-023-03041-2
Khosrow-Khavar F, Filion KB, Bouganim N, Suissa S, Azoulay L. Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study. Circulation. 2020;141(7):549-59. doi: https://doi.org/10.1161/CIRCULATIONAHA.119.044750
Alomar O, Okunade KS, Varkaneh HK, Ghourab G, Alsourani JA, Alras KA, et al. The Effect of Anastrozole on the Lipid Profile: Systematic Review and Meta-analysis of Randomized Controlled Trials. Clin Ther. 2022;44(9):1214-24. doi: https://doi.org/10.1016/j.clinthera.2022.08.003
Wang X, Zhu A, Wang J, Ma F, Liu J, Fan Y, et al. Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study. Ther Adv Med Oncol. 2020;12:1758835920925991. doi: https://doi.org/10.1177/1758835920925991
Kamaraju S, Shi Y, Smith E, Nattinger AB, Laud P, Neuner J. Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study. Clin Cardiol. 2019;42(1):93-100. doi: https://doi.org/10.1002/clc.23114
Shekarforoush S, Koohpeyma F, Safari F. Alteration at transcriptional level of cardiac renin-angiotensin system by letrozole treatment. Acta Cardiol. 2019;74(2):109-13. doi: https://doi.org/10.1080/00015385.2018.1472840
Yin Y, Jin L, Chu M, Zhou Y, Tu S, Cheng Y, et al. Association between endocrine therapy and cognitive decline in breast cancer based on propensity score matching. Front Med (Lausanne). 2023 Jan 26;10:1132287. doi: https://doi.org/10.3389/fmed.2023.1132287
Barber M, Nguyen LS, Wassermann J, Spano JP, Funck-Brentano C, Salem JE. Cardiac arrhythmia considerations of hormone cancer therapies. Cardiovasc Res. 2019;115(5):878-94. doi: https://doi.org/10.1093/cvr/cvz020
He T, Li X, Li J, Wang Z, Fan Y, Li X, et al. Lipid Changes During Endocrine Therapy in Breast Cancer Patients: The Results of a 5-Year Real-World Retrospective Analysis. Front Oncol. 2022;11:670897. doi: https://doi.org/10.3389/fonc.2021.670897
Guida JL, Ahles TA, Belsky D, Campisi J, Cohen HJ, DeGregori J, et al. Measuring Aging and Identifying Aging Phenotypes in Cancer Survivors. J Natl Cancer Inst. 2019;111(12):1245-54. doi: https://doi.org/10.1093/jnci/djz136
Gorgoulis V, Adams PD, Alimonti A, Bennett DC, Bischof O, Bishop C, et al. Cellular Senescence: Defining a Path Forward. Cell. 2019;179(4):813-27. doi: https://doi.org/10.1016/j.cell.2019.10.005
Cuollo L, Antonangeli F, Santoni A, Soriani A. The Senescence-Associated Secretory Phenotype (SASP) in the Challenging Future of Cancer Therapy and Age-Related Diseases. Biology (Basel). 2020;9(12):485. doi: https://doi.org/10.3390/biology9120485
Duan R, Fu Q, Sun Y, Li Q. Epigenetic clock: A promising biomarker and practical tool in aging. Ageing Res Rev. 2022;81:101743. doi: https://doi.org/10.1016/j.arr.2022.101743
Kohli J, Wang B, Brandenburg SM, Basisty N, Evangelou K, Varela-Eirin M, et al. Algorithmic assessment of cellular senescence in experimental and clinical specimens. Nat Protoc. 2021;16(5):2471-98. doi: https://doi.org/10.1038/s41596-021-00505-5
St Sauver JL, Weston SA, Atkinson EJ, Mc Gree ME, Mielke MM, White TA, et al. Biomarkers of cellular senescence and risk of death in humans. Aging Cell. 2023;22(12):e14006. doi: https://doi.org/10.1111/acel.14006
Safwan-Zaiter H, Wagner N, Wagner KD. P16INK4A-More Than a Senescence Marker. Life (Basel). 2022;12(9):1332. doi: https://doi.org/10.3390/life12091332
Wagner S, Prigge ES, Wuerdemann N, Reder H, Bushnak A, Sharma SJ, et al. Evaluation of p16INK4a expression as a single marker to select patients with HPV-driven oropharyngeal cancers for treatment de-escalation. Br J Cancer. 2020;123(7):1114-22. doi: https://doi.org/10.1038/s41416-020-0964-x
Evangelou K, Lougiakis N, Rizou SV, Kotsinas A, Kletsas D, Muñoz-Espín D, et al. Robust, universal biomarker assay to detect senescent cells in biological specimens. Aging Cell. 2017;16(1):192-7. doi: https://doi.org/10.1111/acel.12545
de Mera-Rodríguez JA, Álvarez-Hernán G, Gañán Y, Martín-Partido G, Rodríguez-León J, Francisco-Morcillo J. Is Senescence-Associated β-Galactosidase a Reliable in vivo Marker of Cellular Senescence During Embryonic Development? Front Cell Dev Biol. 2021;9:623175. doi: https://doi.org/10.3389/fcell.2021.623175
Georgakopoulou EA, Tsimaratou K, Evangelou K, Fernandez Marcos PJ, Zoumpourlis V, Trougakos IP, et al. Specific lipofuscin staining as a novel biomarker to detect replicative and stress-induced senescence. A method applicable in cryo-preserved and archival tissues. Aging (Albany NY). 2013;5(1):37-50. doi: https://doi.org/10.18632/aging.100527
Kumari R, Jat P. Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype. Front Cell Dev Biol. 2021;9:645593. doi: https://doi.org/10.3389/fcell.2021.645593
Li Q, Liu F, Tang Y, Lee S, Lang C, Bai L, Xia Y. The Distribution of Cardiovascular-Related Comorbidities in Different Adult-Onset Cancers and Related Risk Factors: Analysis of 10 Year Retrospective Data. Front Cardiovasc Med. 2021;8:695454. doi: https://doi.org/10.3389/fcvm.2021.695454
Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-47. doi: https://doi.org/10.1161/01.cir.97.18.1837
Visseren FL, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-37. doi: https://doi.org/10.1093/eurheartj/ehab484
Hamczyk MR, Nevado RM, Barettino A, Fuster V, Andrés V. Biological Versus Chronological Aging: JACC Focus Seminar. J Am Coll Cardiol. 2020;75(8):919-30. doi: https://doi.org/10.1016/j.jacc.2019.11.062
Obisesan OH, Osei AD, Uddin SM, Dzaye O, Blaha MJ. An Update on Coronary Artery Calcium Interpretation at Chest and Cardiac CT. Radiol Cardiothorac Imaging. 2021;3(1):e200484. doi: https://doi.org/10.1148/ryct.2021200484
Mohan J, Bhatti K, Tawney A, Zeltser R. Coronary Artery Calcification. [Updated 2023 Nov 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519037/
Mitchell JD, Cehic DA, Morgia M, Bergom C, Toohey J, Guerrero PA, et al. Cardiovascular Manifestations From Therapeutic Radiation: A Multidisciplinary Expert Consensus Statement From the International Cardio-Oncology Society. JACC CardioOncol. 2021;3(3):360-80. doi: https://doi.org/10.1016/j.jaccao.2021.06.003
El-Sabbagh A, Osman MM, Fesler M, Helmy T, Parker N, Muzaffar R. Chemotherapy-induced coronary arteries calcium score deterioration as detected with unenhanced CT portion of FDG PET/CT. Am J Nucl Med Mol Imaging. 2018;8(5):303-10.
Zhou F, Zhu X, Liu Y, Sun Y, Zhang Y, Cheng D, et al. Coronary atherosclerosis and chemotherapy: From bench to bedside. Front Cardiovasc Med. 2023;10:1118002. doi: https://doi.org/10.3389/fcvm.2023.1118002
Cadeddu Dessalvi C, Deidda M, Giorgi M, Colonna P. Vascular Damage - Coronary Artery Disease. J Cardiovasc Echogr. 2020;30(Suppl 1):S11-S16. doi: https://doi.org/10.4103/jcecho.jcecho_3_19
Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of Anthracyclines. Front Cardiovasc Med. 2020;7:26. https://doi.org/10.3389/fcvm.2020.00026
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
